Medical University of Vienna to partner with bio.logis GIM in pharmacogenetics

MUW will implement bio.logis Genetic Information Management Suite (GIMS) / platform for the automatic creation and online display of diagnostic reports and treatment recommendations/safety code card for patients

Within the framework of U-PGx, an EU project for promoting the use of pharmacogenetic insights in healthcare, the Medical University of Vienna (MUW) will implement the Genetic Information Management Suite (GIMS) developed by bio.logis Genetic Information Management GmbH. The platform is the first of its kind to largely automatically translate genetic analysis results from laboratories into easily understood diagnostic reports, including the right treatment recommendations from the internationally renowned KNMP (the Royal Dutch Pharmacists Association). Here, the MUW uses the Diagnostic Report Module (GIMS.DRM) in combination with a QR-based safety code card, developed by MUW, for patients. This card is used to make patients’ personal analysis results accessible.

There is still far more scope in medical practice to use pharmacogenetic insights. The EU-funded project Ubiquitous Pharmacogenomics (U-PGx) would like to support this because pharmacogenetics enables important progress in personalized medicine. As a key partner of the U-PGx project, bio.logis GIM has implemented its Genetic Information Management Suite (GIMS) at selected university hospitals and institutions in various European countries, including the Medical University of Vienna.

bio.logis and MUW have now agreed to offer the safety code card—an emergency card for patients, the size of a credit card—beyond the scope of the U-PGx project. A QR code printed on the card gives patients an easy and quick access to a web portal which provides dosing recommendations based on the patient´s genetic analysis. These recommendations will support the attending physician in prescribing the right medication in the right dosage.

“Within the framework of U-PGx, the bio.logis Genetic Information Management Suite enables us to automate and speed up the creation and delivery of easily understood genetic-diagnostic reports,” says Assoc.-Prof. Matthias Samwald, MUW, who is also one of the U-PGx project leaders. “We will offer the products jointly developed during our cooperation also outside of this project.”
bio.logis GIMS works with pre-configured standardized expert knowledge. With the system’s Diagnostic Report Module (GIMS.DRM), creating a genetic-diagnostic report is done in a matter of seconds. An enormous time and cost saver, compared to traditional methods. The Delivery Module (GIMS.DM) can then be used by authorized physicians or the patients themselves to fetch these reports. The safety code card supplements the information for the patients.

“Our expert team, consisting of experienced specialists in human genetics diagnostics, biologists and IT professionals, has developed bio.logis GIMS—a software platform using special algorithms, workflows and modular components for creating genetic-diagnostics reports and making them available at the point of care in very short time,” emphasizes Prof. Daniela Steinberger, Medical Managing Director, bio.logis GIM.
One of the most important considerations for bio.logis in every development is the security and protection of personal data. The system itself processes exclusively pseudonymized analysis data. Every communication channel is generally encrypted. This ensures that the allocation of analysis results to individuals can only be done by the responsible medical staff within the clinic. bio.logis complies with existing data security regulations including the EU-wide General Data Protection Regulation (GDPR), coming into force on May 25, 2018.

Source: https://www.biologis.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies DNA collisions driving genetic changes in cancer